DV
Dividend Vision

SNTI — Senti Biosciences Inc

Senti Biosciences Inc (SNTI)

Total return is -99.6% over the past 5.2 years, 198.5 points behind SPY at 98.9%. Its deepest 1-year drawdown was 85.7%.

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company developing cell and gene therapies using gene circuit platform technologies, with a focus on CAR-NK cell therapies for blood cancers and solid tumors. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotechnology with potential for significant long-term capital appreciation, though it carries the substantial risks typical of clinical-stage drug development companies.

SNTI key facts

Asset type
Stock
Asset class
Equity
Inception date
05/26/2021
Last close
$0.45
Market cap
$14,339,044
Average volume
603600.0
Beta
2.052
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.46